Intangible Assets

3 Months Ended

Mar. 31, 2019

Intangible Assets [Abstract]

Intangible Assets

Note 5 – Intangible Assets

As of March 31, 2019, $1,223,000 was for IPR&D resulting from the Merger’s preliminary purchase price allocation. See Note 3.

As of December 31, 2018, the balance of $41,692 consisted of NIH licensing fees. This balance was expensed into research and development costs during the three months ended March 31, 2019.